Molnupiravir是抗病毒核糖核苷类似物β-D-N4-hydroxycytidine (NHC)的5′-isobutyrate前体药物。
Cas No.:2492423-29-5; 2349386-89-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Molnupiravir is the 5′-isobutyrate prodrug of the antiviral ribonucleoside analogue β-D-N4-hydroxycytidine (NHC) [1]. Molnupiravir rapidly appears in plasma and is converted to the triphosphate form in cells, which is incorporated into viral RNA in place of cytosine or uracil by RNA-dependent RNA polymerase (RdRp), causing a break of viral replication[2]. Molnupiravir has been used as an oral antiviral drug to inhibit various RNA virus infections in different cell models and animal models[3].
In vitro, Molnupiravir treatment for 48 hours significantly inhibited the replication of WT SARS-CoV-2 and Omicron SARS-CoV-2 in Calu-3 cells, with IC50 values of 1.965μM and 0.7556μM, respectively[4]. 62.5 μM of Molnupiravir treatment for 72 hours inhibited viral release and replication in fcwf-4 cells infected with Alphacoronavirus suis[5]. Treatment of Vero cells with 96μM of Molnupiravir for 1 hour significantly reduced the viral genome copy number and viral titer of porcine epidemic diarrhea virus, and maintained the normal morphology of the cells[6].
In vivo, Molnupiravir treatment via intragastrical administration (500mg/kg) once 2 hours before MERS-CoV infection, as well as at 12 hours, 24 hours, and 48 hours after infection, can improve lung function, reduce virus titer, and alleviate weight loss in hDPP4 288/330 gene-modified mice [7]. Oral administration of Molnupiravir (100mg/kg) twice daily to female ferrets within 3.5 days after infection with H1N1 influenza virus significantly reduced viral load, alleviated fever, airway epithelial tissue pathological changes, and inflammation[8].
References:
[1] Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment[J]. Biomedicine & Pharmacotherapy, 2021, 139: 111642.
[2] Bekheit M S, Panda S S, Girgis A S. Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2[J]. European Journal of Medicinal Chemistry, 2023, 252: 115292.
[3] Malek R J, Bill C A, Vines C M. Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19[J]. Biomedicine & Pharmacotherapy, 2021, 144: 112276.
[4] Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination[J]. Cell research, 2022, 32(3): 322-324.
[5] Doki T, Shinohara K, To K, et al. Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells[J]. Pathogens, 2025, 14(8): 787.
[6] Huang Z X, Zhou S T, Yang Z B, et al. Molnupiravir inhibits porcine epidemic diarrhea virus infection in vitro[J]. Viruses, 2023, 15(6): 1317.
[7] Sheahan T P, Sims A C, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice[J]. Science translational medicine, 2020, 12(541): eabb5883.
[8] Toots M, Yoon J J, Cox R M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia[J]. Science translational medicine, 2019, 11(515): eaax5866.
Molnupiravir是抗病毒核糖核苷类似物β-D-N4-hydroxycytidine (NHC)的5′-isobutyrate前体药物[1]。Molnupiravir在血浆中迅速转化，并在细胞内磷酸化为三磷酸形式，通过RNA依赖性RNA聚合酶(RdRp)替代胞嘧啶或尿嘧啶掺入病毒RNA，从而阻断病毒复制[2]。Molnupiravir已作为口服抗病毒药物，广泛应用于多种细胞模型和动物模型中抑制RNA病毒感染[3]。
在体外，Molnupiravir处理48小时可显著抑制WT SARS-CoV-2和Omicron SARS-CoV-2变异株在Calu-3细胞中的复制，IC50值分别为1.965μM和0.7556μM[4]。62.5μM的Molnupiravir处理72小时抑制感染Alphacoronavirus suis的fcwf-4细胞中的病毒释放和复制[5]。用96µM的Molnupiravir处理Vero细胞1小时，显著降低猪流行性腹泻病毒的基因组拷贝数和病毒滴度，并维持细胞正常形态[6]。
在体内，在MERS-CoV感染前2小时及感染后12、24、48小时分别灌胃给予500mg/kg剂量的Molnupiravir，可改善hDPP4 288/330基因改造小鼠的肺功能，降低病毒滴度并缓解体重下降[7]。在感染H1N1型流感病毒后的3.5天内，对雌性雪貂每日两次口服给予Molnupiravir（100mg/kg），显著降低了病毒载量，缓解了发热症状、减轻了气道上皮组织的病理变化以及炎症反应[8]。
| Cell experiment [1]: | |
Cell lines | Vero cells |
Preparation Method | Vero cells were cultured in Dulbecco Modified Eagle Medium (DMEM), containing 10% fetal bovine serum, in a 37°C CO₂ incubator. Vero cells were seeded in 12-well cell culture plates (2×105 cells per well), and Porcine epidemic diarrhea virus (PEDV) [infection multiplicity (MOI)=0.1] and different concentrations of Molnupiravir (0, 1.5, 3.0, 6.0, 12.0, 24.0, 48.0, 96.0, and 192.0µM) were added. The plates were incubated at 4°C for 1 hour. The blank control group used DMSO. Then, the culture medium was discarded, and the plates were washed three times with pre-cooled phosphate-buffered saline (PBS). The viral infection level was quantified by RT-qPCR. |
Reaction Conditions | 0, 1.5, 3.0, 6.0, 12.0, 24.0, 48.0, 96.0, and 192.0µM; 1h |
Applications | Molnupiravir reduced the viral genome copy number and viral titer of PEDV in Vero cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female ferrets |
Preparation Method | Female ferrets (6 to 8 months old) were housed in an ABSL-2 (animal biosafety level 2) facility. After a one-week rest, the ferrets were weighed and randomly grouped. Ferrets were anesthetized and intranasally infected with 1×105 pfu [A/California/07/2009 (H1N1)] (infection volume=200μl). Within 3.5 days after infection (pI), Molnupiravir (100mg/kg) was administered orally twice daily, and the control group received the same volume of solvent (1% methylcellulose aqueous solution). Implantable telemetry sensors were used to continuously monitor body temperature (readings taken every 2 to 15 minutes). Nasal rinse fluid (collected every 12 hours) and nasal concha (upper respiratory tract) samples were collected to detect viral load. |
Dosage form | 100mg/kg; twice day for 3.5 days; p.o. |
Applications | Molnupiravir administration alleviated fever and reduced virus load in influenza virus-infected ferrets. |
References: | |
| Cas No. | 2492423-29-5; 2349386-89-4 | SDF | |
| 别名 | 莫那比拉韦,EIDD-2801; MK-4482 | ||
| 分子式 | C13H19N3O7 | 分子量 | 329.31 |
| 溶解度 | DMSO : 100 mg/mL (303.67 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0367 mL | 15.1833 mL | 30.3665 mL |
| 5 mM | 607.3 μL | 3.0367 mL | 6.0733 mL |
| 10 mM | 303.7 μL | 1.5183 mL | 3.0367 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet